J INTS BIO, AACR 2024 - 'JIN-A02', a Novel Oral 4th Generation EGFR TKI, showing Clinical Benefits in the Ongoing Phase 1 Study

This ongoing Phase 1 clinical study is currently in its 4^th Dose Level of 100mg daily and patients have showed increasing clinical benefits with each increasing dose levels. To-date, Partial Response (PR) was confirmed in one subject on the prior dose level of 50mg daily and stable diseases in two other subjects separately in Dose Level 50mg and 25mg daily.

Despite the initial low doses, JIN-A02 has showed clinical benefits immediately, cumulating in a Partial Response at the 3^rd Dose Level of 50mg, which is an encouraging result in such an early stage of clinical development, the company explained. Furthermore, JIN-A02 has showed a favorable safety profile with no cardiotoxicity, rash or diarrhea reported, even at the current Dose Level of 100mg daily and the longest duration of treatment is over 8 months and still continuing, the company added. The 5^th Dose Level of 150mg daily is expected to begin in 3Q 2024.

J INTS BIO confirmed the favorable safety and efficacy signals of 'JIN-A02' with clinical benefits in this poster presentation in San Diego and greater clinical impact is expected as the study progresses.

Photo - https://mma.prnewswire.com/media/2384471/Professor_Cho_Byoung_Chul_a_conversation_poster_presentation_Phase_1.jpg 
Photo - https://mma.prnewswire.com/media/2384472/Lung_CT_scan_image_lobe_tumor_lesion_21mm___10mm.jpg

View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-aacr-2024--jin-a02-a-novel-oral-4th-generation-egfr-tki-showing-clinical-benefits-in-the-ongoing-phase-1-study-302114160.html